Pfizer sells Irish manufacturing facility to Amgen
March 14, 2011Manufacturing and Production Amgen, Dun Laoghaire, Ireland, Pfizer, pharma manufacturing, pharma manufacturing in Ireland
Amgen has come to the rescue of 280 workers whose jobs were threatened by the closure of a manufacturing facility …
Diabetes trial disappointment for GSK and Tolerx
March 14, 2011Research and Development DEFEND-1, DEFEND-2, GSK, GlaxoSmithKline, Tolerx, diabetes, otelixizumab, type I diabetes
GSK and Tolerx’s type I diabetes drug otelixizumab has failed to meet its primary endpoint in a late-stage trial. Anti-CD3 …
Anticipating the competition in pharma
March 14, 2011Sales and Marketing business intelligence, competitor intelligence, market research
Sun Tzu, the ancient Chinese military strategist wrote: “Conquerors estimate before the war begins, and they consider everything; the defeated …
NICE rejects PharmaMar’s ovarian cancer drug Yondelis
March 14, 2011Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer
NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …
Former Gates Foundation director joins Sanofi
March 14, 2011Research and Development Dr Richard Klausner, Sanofi-Aventis, appointment, research and development
Sanofi-Aventis has appointed a former Gates Foundation director to chair its strategic development and scientific advisory council. Dr Richard Klausner …
Perry Evans to lead RSA Interims
March 11, 2011Business Services, Sales and Marketing Perry Evens, RSA Interims, appointment, business services, rsa, sales and marketing
UK-based life science search company RSA has appointed Perry Evans director of RSA Interims. He joined the company in 2006 …
Sanofi lung cancer drug fails in late-stage trial
March 11, 2011Research and Development Cancer, NSCLC, Regeneron, Sanofi-Aventis, aflibercept, non-small cell lung cancer
Sanofi-Aventis’ lung cancer drug aflibercept has failed to meet its primary endpoint in a phase III trial. The late-stage VITAL …
UK dementia awareness campaign launched
March 11, 2011Medical Communications dementia, disease awareness, disease awareness campaigns, stroke
The Department of Health has launched a £1.2 million awareness campaign which aims to alert people to the early signs …
Tangles and plaques: unlocking the secrets of Alzheimer’s disease
March 11, 2011Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, bapineuzumab, dimebon, latrepirdine, solanezumab
Despite many years of relentless research efforts, Alzheimer’s disease, the most common form of dementia, remains impossible to cure. According …
US approval for GSK’s lupus treatment Benlysta
March 10, 2011Sales and Marketing Benlysta, GSK, GlaxoSmithKline, Human Genome Sciences, Lupus, belimumab, systemic lupus erythematosus
GlaxoSmithKline’s lupus treatment Benylsta has won an historic approval in the US, but will have to prove its safety record …
Matthew Kent moves to 90TEN Healthcare
March 10, 2011Medical Communications 90Ten Healthcare, Matthew Kent, appointment, medical communications
90TEN Healthcare has appointed Matthew Kent as an associate director and to its senior management team. He joins the company …
New skills and ways of working in healthcare comms
March 10, 2011Medical Communications HCA, Healthcare Communications Association, benchmarking
A new report from the Healthcare Communications Association (HCA) indicates a trend towards new skills and ways of working, as …
Novartis’ COPD drug recommended for FDA approval
March 10, 2011Sales and Marketing Arcapta Neohaler, COPD, Novartis, Onbrez Breezhaler, QAB143, chronic obstructive pulmonary disease, indacterol
Novartis has won the backing of an FDA advisory committee for its chronic obstructive pulmonary disease (COPD) treatment QAB149. The …
‘This R&D Malarkey, it’s broken, isn’t it?’
March 9, 2011Research and Development R&D, Sandwich, research productivity
Pharmaceutical industry leaders are increasingly admitting that the very low productivity of its R&D pipelines is unsustainable – but no …
Francois Meyer to head up TxCell
March 9, 2011Research and Development Francois Meyer, TxCell, appointment, research and development
French biotech TxCell has appointed François Meyer as chief executive. He has more than 25 years of pharma and biotech …
Janssen’s monthly antipsychotic approved in Europe
March 9, 2011Sales and Marketing Janssen, Xeplion, antipsychotic, injectible antipsychotic, paliperidone palmitate, schizophrenia
Janssen’s injectable antipsychotic Xeplion has been approved by the European Commission for the treatment of schizophrenia. There is no cure …
Actelion defends itself against investor aggression
March 9, 2011Sales and Marketing Actelion, Tracleer, almorexant
Swiss biotech firm Actelion is mounting a defence of its management board and strategy following an offensive by a shareholder …
Finance a bigger worry than reform for NHS chiefs
March 9, 2011Acute Trusts, NHS, NHS Confederation, NHS finances, NHS reforms
NHS leaders are more concerned with how they are going to balance the books this year than with the reorganisation …
AZ partners with Galderma on psoriasis research
March 9, 2011Research and Development AZ, AstraZeneca, Galderma, dermatology, psoriasis
AstraZeneca has signed a five-year deal with dermatology specialist Galderma Pharma to develop new treatments for conditions including psoriasis. It …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
